Archive
FTSE 100 closes higher, bolstered by Aveva and AstraZeneca; Boris Johnson to seek December general election
The blue-chip benchmark finished ahead by 67.51 points at 7,328.25 on the day
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 32 of 55
AstraZeneca likely to remain in favour, banks update on PPI
Prudential completes its M&G demerger on Monday, with the week also seeing WPP and Travis Perkins follow recent profit warnings from rivals and Reckitt Benckiser's new CEO makes his debut
FDA grants “priority review” status to AstraZeneca’s breast cancer antibody
“Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer"
AstraZeneca gets US clearance for asthma pen
Fasenra sales surged 244% in its latest quarter to US$296mln as it became the preferred novel-biologic medicine for the treatment of severe asthma.
IPO Roundup: Several biotech companies set to go public this week; WeWork cancels its IPO filing
ADC Therapeutics, a Swiss biotech, expects to lead the pack with a $200 million offering
Glaxo and AstraZeneca vie for position with "unprecedented" ovarian cancer trials
Both pharma companies' PARP inhibitor drugs reduced disease progression and death by up to 40% in clinical trials
AstraZeneca shares hit all-time highs as it adds colour to recent trial data
Top-line data earlier this year only revealed that the drugs in those studies achieved “statistically significant” results, but Astra has now been able to quantify their effects
AstraZeneca scores another late-stage win, this time with COPD drug
Breztri Aerosphere, even when taken in smaller doses, was shown to be much more effective in reducing the number of exacerbations suffered by COPD patients than current drugs
Amryt Pharma: The AIM drug developer potentially sitting on a US$100mln piece of paper
Amryt has a chance of being awarded a priority review voucher, which sell for several times more than the company’s current market cap
AstraZeneca scores another regulatory win in China for roxadustat anaemia drug
Astra will now be able to treat all Chinese patients living with chronic kidney disease who experience anaemia, regardless of whether they require dialysis
AstraZeneca’s cancer drug combo stumbles in phase III lung cancer trial
Astra had been hoping to show that the combination of Imfinzi and tremelimumab was more effective in treating certain lung cancer patients than chemo
AstraZeneca nears £100bn market cap as remarkable drug pipeline turnaround continues
Only five years ago, AstraZeneca’s Symbicort inhaler generated more sales than all of the firm’s cancer drugs combined. The same can’t be said any more…
AstraZeneca pumps higher as Farxiga shows benefit in late-stage heart-failure study
Farxiga, when combined with current standard of care, was able to reduce the risk of cardiovascular death and the worsening of heart failure
AstraZeneca’s Lynparza meets primary endpoint in late-stage ovarian cancer trial
AstraZeneca is competing with GSK to win the race to become the go-to maintenance treatment for people who have been treated for ovarian cancer
AstraZeneca’s market value swells by £4bn after forecast-busting second-quarter results
Revenue beat forecasts by 5%, while operating profit was particularly impressive, coming in some 17% ahead of expectations
Archive
FTSE 100 closes in red Thursday as ECB update underwhelms
There were mixed messages in Mario Draghi's update on Thursday
Archive
Day ahead preview: Unilever, National Express, Diageo, ECB
With a slew of corporate earnings and the European Central Bank's policy decision, Thursday will be a busy day of news
GSK names former AstraZeneca finance boss as new chairman
Jonathan Symonds will be the man tasked with overseeing the mega merger of GSK and Pfizer’s consumer healthcare businesses
Archive
ITV investors hope for Love Island boost amid tough ad market
The week ahead includes updates from ITV, Unilever, Rightmove, Diageo, Marston's, IG Group, National Express, GSK and AstraZeneca
GlaxoSmithKline edges higher as Zejula passes late-stage ovarian cancer study with flying colours
Zejula demonstrated a “statistically significant” improvement in progression free survival – the length of time a patient lives with the disease but it doesn’t get worse